P1140: TIME TO TUMOR, SYMPTOMATIC AND LABORATORY RESPONSES FOLLOWING SILTUXIMAB TREATMENT IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE

por van Rhee, F., Rosenthal, A., Kanhai, K., Martin, R., Nishimura, K., Hoering, A., Fajgenbaum, D.
Publicado 2022

Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma

por Heuck, C J, Qu, P, van Rhee, F, Waheed, S, Usmani, S Z, Epstein, J, Zhang, Q, Edmondson, R, Hoering, A, Crowley, J, Barlogie, B
Publicado 2014

The Clinical Value of Molecular Subtyping Multiple Myeloma Using Gene Expression Profiling

por Weinhold, N, Heuck, C, Rosenthal, A, Thanendrarajan, S, Stein, C, Van Rhee, FV, Zangari, M, Hoering, A, Tian, E, Davies, FE, Barlogie, B, Morgan, GJ
Publicado 2015

Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma

por Khan, R, Apewokin, S, Grazziutti, M, Yaccoby, S, Epstein, J, van Rhee, F, Rosenthal, A, Waheed, S, Usmani, S, Atrash, S, Kumar, S, Hoering, A, Crowley, J, Shaughnessy, J D, Barlogie, B
Publicado 2015

Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211

por Usmani, S Z, Sexton, R, Ailawadhi, S, Shah, J J, Valent, J, Rosenzweig, M, Lipe, B, Zonder, J A, Fredette, S, Durie, B, Hoering, A, Bartlett, B, Orlowski, R Z
Publicado 2015

P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-12...

por Usmani, S., Hoering, A., Ailawadhi, S., Sexton, R., Lipe, B., Valent, J., Rosenzweig, M., Zonder, J., Dhodapkar, M., Callander, N., Zimmerman, T., Voorhees, P., Durie, B., Rajkumar, S. V., Richardson, P., Orlowski, R.
Publicado 2022

Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of...

por Papanikolaou, X, Rosenthal, A, Dhodapkar, M, Epstein, J, Khan, R, van Rhee, F, Jethava, Y, Waheed, S, Zangari, M, Hoering, A, Crowley, J, Alapat, D, Davies, F, Morgan, G, Barlogie, B
Publicado 2016

Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma

por Jethava, Y, Mitchell, A, Zangari, M, Waheed, S, Schinke, C, Thanendrarajan, S, Sawyer, J, Alapat, D, Tian, E, Stein, C, Khan, R, Heuck, C J, Petty, N, Avery, D, Steward, D, Smith, R, Bailey, C, Epstein, J, Yaccoby, S, Hoering, A, Crowley, J, Morgan, G, Barlogie, B, van Rhee, F
Publicado 2016

Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma

por Jethava, Y, Mitchell, A, Zangari, M, Waheed, S, Schinke, C, Thanendrarajan, S, Sawyer, J, Alapat, D, Tian, E, Stein, C, Khan, R, Heuck, C J, Petty, N, Avery, D, Steward, D, Smith, R, Bailey, C, Epstein, J, Yaccoby, S, Hoering, A, Crowley, J, Morgan, G, Barlogie, B, van Rhee, F
Publicado 2016